Health TrialsbyHealthPanel

REtinal Detachment Outcomes Study

ConditionRetinal Detachment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCHU de Quebec-Universite Laval

About this trial

Background: Few large randomized controlled trials provide strong evidence to guide surgical repair of primary rhegmatogenous retinal detachment (RRD) repair. The purpose of this factorial, single-blind, randomized controlled trial is to analyze and compare the surgical outcomes, functional visual outcomes, complications, and quality of life associated with RRD repair using (A) pars plana vitrectomy only (PPV) or PPV with scleral buckle (PPV-SB) and (B) sulfur hexafluoride gas (SF6) or perfluoropropane gas (C3F8) tamponade.

Methods: Eligible patients with moderately complex RRD will be randomized 1:1 to PPV or PPV-SB and 1:1 to SF6 or C3F8 gas tamponade. Approximately 560 patients will be recruited to be able to detect a difference of around 10% in SSAS rate between groups. Patients will be followed using multimodal imaging and quality of life questionnaires before and after the surgical repair until 1 year postoperative. The primary outcome will be single surgery anatomic success (SSAS), defined as absence of reoperation for recurrent RRD in the operating room. Secondary outcomes will be pinhole visual acuity (PHVA) at 8-10 weeks and 6 months, final best-corrected visual acuity (BCVA), final retina status (i.e., attached or detached), time to onset of RRD recurrence, severity and number of complications, and questionnaire results.

Discussion: This will be the first 2 × 2 factorial randomized controlled trial examining repair techniques in primary RRD. It will also be the first randomized controlled trial to compare gas tamponade between the two most common agents. Notably, it will be adequately powered to detect a clinically significant effect size. The use of multimodal imaging will also be a novel aspect of this study, allowing us to compare head-to-head the impact of adding an SB to the retina's recovery after RRD repair and of differing gas tamponades. Until now, the treatment of RRD has been largely guided by pragmatic retrospective cohort studies. There is a lack of strong evidence guiding therapeutic decisions and this trial will address (1) whether supplemental SB is justified and (2) whether longer duration gas tamponade with C3F8 is necessary.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years

Diagnosis of rhegmatogenous retinal detachment

Disqualifiers

Proliferative vitreoretinopathy (PVR) grade ≥C2

Chronic RRD with duration >3 months

Proliferative diabetic retinopathy with tractional retinal detachment (RD)

Macular holes

Trial design

Design model

Factorial

Treatments tested in this trial

  • Pars plana vitrectomy

    Procedure/Surgery

    Pars plana vitrectomy will be performed in a standard fashion starting with central vitrectomy, then by localizing retinal breaks, and marking them with endodiathermy. Perfluorocarbon will be used to displace subretinal fluid which will be aspirated at its exit from the retinal break as much as possible and maximal vitreous base shaving will be performed in all cases. This will be followed by an air-fluid exchange. Use of cryotherapy to solidify the retina intraoperatively and use of internal limiting membrane peeling of the posterior pole will be at the discretion of the surgeon. In all cases, laser photocoagulation around retinal breaks, holes, areas of lattice degeneration, and posterior to sclerotomy sites will be done and then a 360° laser retinopexy will be performed at the surgeon's discretion and consisted of three rows of medium-white burns anterior to the level of the vortex vein, towards and beyond the equator.

  • Pars plana vitrectomy with scleral buckle

    Procedure/Surgery

    In cases with SB, after 360° peritomy and dissection in 4 quadrants, a 41-circling band with 3082 sleeves (Labtician Ophthalmics, Oakville, ON Canada) will be used in all cases and fixed to the sclera at approximatively 11.5 mm from the limbus (or 5.5 from the insertion of rectus muscles) using partial thickness scleral tunnel or mattress sutures with 5.0 prolene or nylon performed in 4 quadrants depending on the surgeon preferences. Pars plana vitrectomy will then be performed as in the PPV only group.

  • Sulfur hexafluoride gas tamponade

    Other intervention

    At the end of the surgery, the eye is filled with sulfur hexafluoride gas tamponade.

  • Perfluoropropane gas

    Other intervention

    At the end of the surgery, the eye is filled with perfluoropropane gas tamponade.

Treatment groups

560 Participants
are divided into 4 treatment groups
Group A: Pars plana vitrectomy + sulfur hexafluoride gas tamponadeActive comparator 2 interventions
Group B: Pars plana vitrectomy with scleral buckle + sulfur hexafluoride gas tamponadeExperimental treatment 2 interventions
Group C: Pars plana vitrectomy + perfluoropropane gas tamponadeExperimental treatment 2 interventions
Group D: Pars plana vitrectomy with scleral buckle + perfluoropropane gas tamponadeExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Single surgery anatomic success

Freedom from reoperation for recurrent RRD

Time frame
Until final 1 year follow-up

Secondary outcomes

1

Pinhole visual acuity

Time frame
8-10 weeks, 6 months
2

Best-corrected visual acuity

Time frame
1 year
3

Time to onset of RD recurrence

Time frame
Until final 1 year follow-up
4

Severity and number of complications

Time frame
Until final 1 year follow-up

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

CHU de Quebec-Universite Laval

Lead sponsor

Fighting Blindness Canada

Collaborator

Source ClinicalTrials.gov
Apply now